Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma
Y.M. Geurts·Michael Schaapveld·J. S. Vermaat·Judith M. Roesink·Erik C. Schimmel·Daphne van Kampen·Augustinus D. G. Krol·Wouter J. Plattel·Lara H. Böhmer·Hein P. J. Visser·Suzanne I.M. Neppelenbroek·Eva de Jongh·Jan-Paul de Boer·R. van Rijn·F. E. van Leeuwen·Karin Müller·L.C.J. te Boome·Francisca Ong·EF Posthuma·Harry R. Koene·Roel J. de Weijer·Cynthia So-Osman·J. G. Zijlstra·Yolande Appelman·Marten R Nijziel·Berthe M P Aleman·Marie José Kersten·Karijn M S Verschueren·Bastiaan D P Ta·D van Spronsen·Yavuz M Bilgin·Cécile P.M. Janus
≥5-year DLBCL survivors have increased risks of developing CVDs, especially HF. Physicians and patients should recognize this risk, and individualized cardiac screening should be considered.